TY - JOUR
T1 - Association of hospital performance measures with readmissions for patients with heart failure
T2 - A report from JROAD-DPC study
AU - Nakao, Kazuhiro
AU - Yasuda, Satoshi
AU - Noguchi, Teruo
AU - Sumita, Yoko
AU - Nakao, Yoko M.
AU - Nishimura, Kunihiro
AU - Nakai, Michikazu
AU - Miyamoto, Yoshihiro
AU - Tsutsui, Hiroyuki
AU - Saito, Yoshihiko
AU - Komuro, Issei
AU - Gale, Chris P.
AU - Ogawa, Hisao
N1 - Funding Information:
The present work was supported in part by a grant from the Ministry of Health, Labour and Welfare of Japan [ H29–31201709018A ] (SY). This work was also supported by Japan Society for the Promotion of Sience KAKENHI Grant Number 17 K09548 (KN) and 20 K08483 (KN) , grant from Japanese Cardiovascular Research Foundation: The Bayer Scholarship for Cardiovascular Research (KN) and research grant from The Japan Research Foundation for Healthy Ageing (KN). The funders had no role in the design and conduct of the study; in the collection, management, analysis, or interpretation of data; in the preparation, review, or approval of the manuscript; or in the decision to submit the manuscript for publication.
Funding Information:
Dr. Yasuda reports grants and personal fees from Takeda, grants and personal fees from Daiichi-Sankyo, personal fees from Bristol-Z, grants and personal fees from Bristol-Myers, grants from Abbot, outside the submitted work. Dr. Tsutsui reports Grants from Daiichi Sankyo, Mitsubishi Tanabe Pharma, Nippon Boehringer Ingelheim, IQVIA Services Japan, Omron Healthcare, MEDINET, Medical Innovation Kyushu, and personal fees from AstraZeneca, Ono Pharmaceutical, Otsuka Pharmaceutical, Daiichi Sankyo, Mitsubishi Tanabe Pharma, Teijin Pharma, Nippon Boehringer Ingelheim, Novartis Pharma, Bayer Yakuhin, Pfizer Japan, Bristol-Myers Squibb, Kowa, and Nippon Rinsho outside the submitted work. Dr. Saito reports receiving personal fees from Mitsubishi Tanabe Pharma Corporation, Otsuka Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Novartis Pharma K·K., Pfizer Japan Inc., and Nippon Boehringer Ingelheim Co. Ltd. Funding/Support: Dr. Saito has received from Mitsubishi Tanabe Pharma Corporation, Otsuka Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Novartis Pharma K.K., Pfizer Japan Inc., Nippon Boehringer Ingelheim Co. Ltd., Ono Pharmaceutical Co. Ltd., St. Jude Medical Japan Co., Ltd., Bayer Holding Ltd., Terumo Corporation, Kyowa Hakko Kirin Co. Ltd., Dainippon Sumitomo Pharma Co. Ltd., Astellas Pharma Inc., Takeda Pharmaceutical Co. Ltd., Teijin Pharma Ltd., Shionogi & Co. Ltd., Kowa Pharmaceutical Co. Ltd., and Actelion Pharmaceuticals Japan Ltd., and also has Endowed department by MSD K.K. outside the submitted work. Dr. Komuro reports grants and personal fees from Takeda Pharmaceutical Company Limited., personal fees from Nippon Boehringer Ingelheim Co., Ltd., personal fees from MSD K.K, grants from Astellas Pharma Inc., grants from Edwards Life sciences Ltd., grants and personal fees from Mitsubishi Tanabe Pharma Corporation, personal fees from Actelion Pharmaceuticals Japan Ltd., grants and personal fees from Daiichi-Sankyo, personal fees from Amgen Astellas BioPharma K.K., grants from Otsuka Pharmaceutical Co. Ltd., Kowa company Ltd. grants from Dainippon Sumitomo Pharma Co. Ltd., grants from TEIJIN PHARMA LIMITED, grants from TOA EIYO LTD, grants from NIPRO CORPORATION, grants from Terumo Corporation, and grants from ONO PHARMACEUTICAL CO. LTD., outside the submitted work.
Funding Information:
Dr. CPG reports honoraria from Astra Zeneca, Amgen, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Menarini, Novartis, Wondr Medical, Vifor Pharma, and research grants from Abbott and BMS outside the submitted work.
Publisher Copyright:
© 2021 Elsevier B.V.
PY - 2021/10/1
Y1 - 2021/10/1
N2 - Background: Measuring quality of care is central to quality improvement. Improving outcomes for heart failure (HF) may relate to hospital care delivery. However, there is limited nationwide data on the relationship between hospital-level HF performance measures and clinical outcomes. Methods: From the Japanese Registry of All cardiac and vascular Diseases (JROAD-DPC) database, 83,567 HF patients hospitalised in 731 certificated hospitals in 2014 by the Japanese Circulation Society were analysed. Five performance measures were prescription rate of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, beta-blocker, and mineralocorticoid receptor antagonist and measurement rate of echocardiography and B-type natriuretic peptide during hospitalisation. Relationships between these measures and 1-year readmission due to HF were analysed. Composite performance score (CPS) obtained from the five performance measures and outcomes were also analysed. We also investigated the relationships between CPS and hospital structural factors. Results: From the cohort (mean age; 78.2 years, woman 48.4%), HF readmission rate at 1 year was 19.6% (n = 16,368). Readmission rate decreased with higher quartiles of prescription rate in each medication and diagnostic performance rates. The highest CPS group was associated with a 15% risk reduction in HF readmission compared with the lowest CPS group (hazard ratio, 0.85, 95% confidence interval [0.80–0.89], p < 0.001) after covariate adjustment. Several structural factors such as number of cardiology specialists, hospital case volume for HF, and presence of cardiac surgery division were associated with high CPS. Conclusion: Higher hospital performance measures for HF were inversely associated with HF readmissions.
AB - Background: Measuring quality of care is central to quality improvement. Improving outcomes for heart failure (HF) may relate to hospital care delivery. However, there is limited nationwide data on the relationship between hospital-level HF performance measures and clinical outcomes. Methods: From the Japanese Registry of All cardiac and vascular Diseases (JROAD-DPC) database, 83,567 HF patients hospitalised in 731 certificated hospitals in 2014 by the Japanese Circulation Society were analysed. Five performance measures were prescription rate of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, beta-blocker, and mineralocorticoid receptor antagonist and measurement rate of echocardiography and B-type natriuretic peptide during hospitalisation. Relationships between these measures and 1-year readmission due to HF were analysed. Composite performance score (CPS) obtained from the five performance measures and outcomes were also analysed. We also investigated the relationships between CPS and hospital structural factors. Results: From the cohort (mean age; 78.2 years, woman 48.4%), HF readmission rate at 1 year was 19.6% (n = 16,368). Readmission rate decreased with higher quartiles of prescription rate in each medication and diagnostic performance rates. The highest CPS group was associated with a 15% risk reduction in HF readmission compared with the lowest CPS group (hazard ratio, 0.85, 95% confidence interval [0.80–0.89], p < 0.001) after covariate adjustment. Several structural factors such as number of cardiology specialists, hospital case volume for HF, and presence of cardiac surgery division were associated with high CPS. Conclusion: Higher hospital performance measures for HF were inversely associated with HF readmissions.
UR - http://www.scopus.com/inward/record.url?scp=85114224714&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85114224714&partnerID=8YFLogxK
U2 - 10.1016/j.ijcard.2021.08.019
DO - 10.1016/j.ijcard.2021.08.019
M3 - Article
C2 - 34419528
AN - SCOPUS:85114224714
SN - 0167-5273
VL - 340
SP - 48
EP - 54
JO - International Journal of Cardiology
JF - International Journal of Cardiology
ER -